American Association for Cancer Research
10780432ccr163029-sup-175056_2_supp_3973332_kk8221.xlsx (4.29 MB)

Supplementary Table 1 from Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations

Download (4.29 MB)
posted on 2023-03-31, 19:24 authored by Adam A. Friedman, Yun Xia, Lorenzo Trippa, Long Phi Le, Vivien Igras, Dennie T. Frederick, Jennifer A. Wargo, Kenneth K. Tanabe, Donald P. Lawrence, Donna S. Neuberg, Keith T. Flaherty, David E. Fisher

Screening results for drug combinations, expressed as percent of control (DMSO-treated) values.



Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Melanoma Research Alliance



Purpose: Successful development of targeted therapy combinations for cancer patients depends on first discovering such combinations in predictive preclinical models. Stable cell lines and mouse xenograft models can have genetic and phenotypic drift and may take too long to generate to be useful as a personalized medicine tool.Experimental Design: To overcome these limitations, we have used a platform of ultra-high-throughput functional screening of primary biopsies preserving both cancer and stroma cell populations from melanoma patients to nominate such novel combinations from a library of thousands of drug combinations in a patient-specific manner within days of biopsy. In parallel, patient-derived xenograft (PDX) mouse models were created and novel combinations tested for their ability to shrink matched PDXs.Results: The screening method identifies specific drug combinations in tumor cells with patterns that are distinct from those obtained from stable cell lines. Screening results were highly specific to individual patients. For patients with matched PDX models, we confirmed that individualized novel targeted therapy combinations could inhibit tumor growth. In particular, a combination of multi-kinase and PI3K/Akt inhibitors was effective in some BRAF–wild-type melanomas, and the addition of cediranib to the BRAF inhibitor PLX4720 was effective in a PDX model with BRAF mutation.Conclusions: This proof-of-concept study demonstrates the feasibility of using primary biopsies directly for combinatorial drug discovery, complementing stable cell lines and xenografts, but with much greater speed and efficiency. This process could potentially be used in a clinical setting to rapidly identify therapeutic strategies for individual patients. Clin Cancer Res; 23(16); 4680–92. ©2017 AACR.